Background: To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged ‡70 years. Results: Ninety-four patients were enrolled. In an intent-to-treat analysis, 2 complete responses (CRs) and 16 partial responses (PRs) were reported with CAPOX (ORR 38%), and 2 CRs and 15 PRs with CAPIRI (ORR 36%; P = 0.831). Median time to progression was 8 months for CAPOX and 7 months for CAPIRI (P = 0.195), with median survival times of 19.3 months and 14.0 months (P = 0.165), respectively. Global health status was improved in 45% and in 21% of patients in the CAPOX and CAPIRI arms, respectively. The most common treatment-related grade 3-4 adverse events in CAPIRI versus CAPOX patients were diarrhea (32% versus 15%; P = 0.052) and neutropenia (23% versus 6%; P = 0.021).
introduction
In Europe, 40% of patients with colorectal cancer (CRC) are diagnosed at the age of 75 years or older [1] . Nevertheless, much of the defining clinical research in this field has excluded subjects of advanced age, making it difficult for clinicians to interpret current treatment paradigms for their older patients [2] .
Oxaliplatin and irinotecan in combination with 5-fluorouracil (5-FU) and bevacizumab are now established as first-line agents in the treatment of metastatic CRC. Although recent pooled analyses show that the efficacy of both oxaliplatinbased and irinotecan-based regimens are maintained in the elderly [3, 4] , experience with these regimens in older patients, particularly those aged >75 years, is very limited in clinical studies. In addition, the inconvenience and discomfort of regular visits for intravenous (i.v.) drug administration and the increased associated risk of infection and thromboembolism are particular problems in the elderly [5, 6] .
Oral capecitabine avoids the cost and inconvenience associated with infusional 5-FU. Two phase III trials have shown that capecitabine single-agent therapy is at least as effective and as well tolerated as 5-FU/leucovorin (LV) as first-line treatment of metastatic CRC [7, 8] . Capecitabine and irinotecan (CAPIRI) is reported to have excellent efficacy, although unacceptable levels of toxicity were reported in some studies with the doses initially selected for this combination [9, 10] . The combination of capecitabine and oxaliplatin (CAPOX) seems to be efficacious and tolerable in older patients [11] [12] [13] . However, no large-scale prospective studies have been conducted in elderly populations with these combinations.
We have conservatively chosen a weekly administration of oxaliplatin and irinotecan to better define the toxicity of both regimens in keeping with a previous randomized phase II study conducted in Germany [14] .
Nevertheless, the primary objective of this multicenter randomized phase II study is to demonstrate that CAPIRI and CAPOX are active in a representative cohort of patients aged ‡70 years with locally advanced or metastatic CRC. The secondary aims are to evaluate the treatments in terms of safety original article *Correspondence to: Dr G. Rosati, Via Sanremo, 197, 85100 Potenza, Italy. Tel: +39-0971-612273; Fax: +39-0971-613000; E-mail: oncogerry@yahoo.it profile, time to disease progression (TTP), overall survival (OS), and quality of life (QoL).
patients and methods

patient selection
This randomized phase II study was conducted at nine centers in Italy. The study protocol was approved by the local ethics committee, registered with the health authorities, and carried out according to the guidelines of Good Clinical Practice and the Declaration of Helsinki. After giving informed consent, patients were included if they met the following eligibility criteria: histologically confirmed metastatic or locally advanced CRC; bidimensionally measurable disease; aged 70 years or more; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of two or less; life expectancy of ‡3 months; and adequate bone marrow, kidney, and liver function. Adjuvant chemotherapy, if administered, must have been completed ‡6 months before study enrollment. Key exclusion criteria were previous chemotherapy for advanced disease, severe cardiac dysfunction, and unresolved or partial bowel obstruction. Palliative radiotherapy was allowed, provided that the target lesion was outside the irradiation fields.
pretreatment evaluation
Within 1 month of starting treatment, all patients underwent a physical examination, PS assessment, routine hematology and biochemistry analyses, ECG, measurement of creatinine clearance, chest X-ray, computed tomography of the abdomen, and, if indicated, of the thorax, at study entry. 
safety and efficacy analyses
Safety analyses included all patients who received at least one dose of study medication. Complete blood cell counts with platelet and differential counts were obtained weekly during chemotherapy. The intensity of clinical adverse events was graded according to the National Cancer Institute Common Toxicity Criteria grading system (version 3.0). All adverse reactions were recorded before each chemotherapy course. Efficacy assessments were carried out after every three cycles of treatment. World Health Organization criteria were used to define response (CR, the complete disappearance of all evident tumor signs as estimated by two observations not less than 4 weeks apart; PR, a > 50% decrease in the sum of the products of the largest perpendicular diameters of all measurable disease without occurrence of new lesions), response duration, TTP, and OS [15] . After completing the study, patients were followed up for any subsequent treatment and survival every 2 months until death, loss to follow-up, or termination of the study. All analyses were carried out on an intention-to-treat basis.
QoL assessment
The European Organization for Research and Treatment of Cancer (EORTC) questionnaire (QLQ-C30) was used to assess QoL [16] . Patients were asked to complete the QoL questionnaire at baseline and after every three cycles of chemotherapy. For the QoL analysis, the mean raw scores of single items were calculated and then transformed linearly, so that all scales ranged from 0 to 100. Median changes in domains during treatment were given as the maximum variation compared with baseline.
treatment modifications
Treatment was interrupted in cases of grade 2 toxicity or worse and was resumed once toxicity improved to grade 0 or 1. For patients experiencing grade 3 and 4 hematological toxicity, treatment was delayed for no more than 2 weeks, and doses of all study drugs were reduced by 20%. For patients who experienced a second occurrence of grade 3-4 toxicity, a further dose reduction of 20% was permitted. Treatment was discontinued in cases of further grade 3-4 toxicity. Days when therapy was withheld because of toxicity were counted as treatment days. In the presence of grade 2-4 diarrhea, capecitabine administration was interrupted until recovery. The drug was then restarted at a 20% reduced dose in cases of grade 3-4 toxicity or after the second appearance of grade 2 diarrhea. If grade ‡ 2 hand-foot syndrome and/or mucositis occurred, capecitabine administration was stopped immediately.
At each visit, returned medication was checked and counted. If the patient stopped treatment for >1 week for any reason other than side effects, they were withdrawn from the trial for noncompliance.
statistical considerations
The Simon two-stage optimal design was used to determine the number of patients to be included. With a 5% alpha risk and 20% beta risk, we determined a first-stage response probability of 20% (which, if true, implied discontinuing the trial) and a minimal rate of efficacy of 30% (which, if true, implied moving on to the second stage of the trial). The number of patients to be included in each arm was calculated to be 24 for the first stage and an additional 23 for the second stage. After the inclusion of 47 patients in each arm, the observation of eight or fewer patients with a clinical response allowed a conclusion of insufficient treatment efficacy. OS and TTP were calculated using the Kaplan-Meier method with 95% confidence intervals (CIs). For the QoL analysis, differences between the scores of the EORTC QLQ-C30 questionnaire scales after every three chemotherapy cycles and baseline scores were compared with the Wilcoxon rank sum test.
results patient characteristics
Between December 2005 and January 2008, a total of 94 patients were entered into the study. Forty-seven patients were randomly allocated to the CAPOX arm and 47 to the CAPIRI arm. As shown in Tables 1 and 2 , the two groups were well matched except that more patients in the CAPOX arm had peritoneal carcinomatosis and ‡1 organs involved than patients in the CAPIRI arm. The median age of all patients was 74 years (range 70-90 years), and 51 patients (54%) were ‡75 years.
treatment
On the cut-off date (3 April 2008) , the median follow-up time for the entire group was 18 months. The median duration of treatment was 4.2 months (range 1-8.4) for the CAPOX group and 3.5 months (range 1-9.8) for the CAPIRI group. A median of six cycles (range 1-12) was administered in the CAPOX group and five cycles (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in the CAPIRI group.
Four patients in the CAPOX arm underwent subsequent complementary locoregional treatment (radiotherapy, n = 1; radiofrequency ablation of liver metastases, n = 3). Overall, 20 patients initially treated with CAPOX were crossed over to irinotecan-based chemotherapy after disease progression, and four patients received other second-line chemotherapy. In the CAPIRI arm, four patients received subsequent locoregional treatment (secondary surgery to remove primary tumor, n = 1; potentially curative liver metastasectomy, n = 1; radiotherapy, n = 2). Oxaliplatin-based chemotherapy was prescribed in 14 patients after disease progression in this arm. At the time of this report, a third-line regimen with cetuximab had been given to 10 patients (CAPOX, n = 4; CAPIRI, n = 6).
efficacy Eighty-one (86%) of 94 patients were assessable for response (Table 3) . Thirteen patients, five in the CAPOX arm and eight in the CAPIRI arm, were not assessable but were included in the intent-to-treat analysis. Three of these patients (CAPOX, n = 1; CAPIRI, n = 2) withdrew consent before the first tumor assessment, four patients (two in each arm) were withdrawn from the study because of early progression, two (one in each arm) died of causes related to treatment, and four (CAPOX, n = 1; CAPIRI, n = 3) interrupted therapy soon after cycle 1 because of side effects and no clinical benefit.
Two complete responses (CRs) and 16 partial responses (PRs) were recorded in the CAPOX arm, for an overall response rate (ORR) of 38% (95% CI 24% to 53%). In the (Figure 1 ). Median OS was 19.3 months (95% CI 10.8-27.7) and 14.0 months (95% CI 9.5-18.4) with CAPOX and CAPIRI, respectively (P = 0.165) (Figure 2 ).
Response rates (RRs) were analyzed in patients aged ‡75 years. A clinical response (one CR and eight PRs) was obtained in nine patients (33%) in the CAPOX arm, and seven PRs (29%) were recorded in the CAPIRI arm. There were no substantially significant differences in terms of TTP and OS among subjects aged ‡75 years in each of the two arms (data not shown).
safety
All 94 patients were assessable for safety. Treatment was discontinued because of toxicity in 11 (23%) CAPIRI recipients (gastrointestinal syndrome, n = 7; hand-foot syndrome, n = 2; and hematological events, n = 2) and four (9%) CAPOX patients (hand-foot syndrome, n = 2; gastrointestinal syndrome, n = 1; and hematological events, n = 1); this difference was statistically significant (P = 0.049). Two treatment-related deaths occurred (myocardial infarction during cycle 2 with CAPOX, n = 1; sepsis with febrile neutropenia during cycle 1 with CAPIRI, n = 1). Sixty-day all-cause mortality was therefore 2%.
Frequent treatment-related severe toxic effects are listed in Table 4 . Severe neurotoxicity occurred in 15% of CAPOX recipients. The most common treatment-related grade 3-4 adverse events in CAPIRI versus CAPOX patients were as follows: diarrhea (32% versus 15%; P = 0.052) and neutropenia (23% versus 6%; P = 0.021).
Severe nausea or emesis, mucositis, anemia, thrombocytopenia, and hand-foot syndrome were rarely observed. Grade 3 hyperbilirubinemia was an isolated laboratory abnormality and occurred in two patients in each arm; it was not accompanied by grade 3 or 4 elevations in alkaline phosphatase or liver transaminases.
Diarrhea was the only treatment-related serious adverse event detectable in patients aged ‡75 years, which was more common in the CAPIRI arm than in the CAPOX arm (8 versus 2, respectively; P = 0.046), whereas neutropenia appeared more frequently in patients aged <75 years in the CAPIRI arm (6 versus 1, respectively; P = 0.050). original article
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Fifty-three patients (56%) received full doses of study drugs throughout the study. Dose reduction was required for irinotecan alone in 18 patients, whereas five patients received reduced doses of both drugs in the CAPIRI arm. CAPOX cycles were administered with a reduced dose of oxaliplatin only in 12 patients, whereas six patients required reduced doses of both drugs. This difference was not statistically significant (P = 0.301). Corresponding figures for at least one infusion delay were 12% and 8%, respectively. Most dose reductions were by one level (reduction to 80% of starting dose). Only five patients (CAPOX, n = 1; CAPIRI, n = 4) required a second-level dose reduction (60% of starting dose). Adverse events most commonly leading to dose reduction and/or delay were diarrhea and neurotoxicity with CAPOX, and diarrhea and neutropenia with CAPIRI. The incidence of dose reductions was similar in the patients aged <75 or ‡75 years (data not shown).
quality of life
Sixty-seven questionnaires were analyzed. Compliance for completion of the QoL questionnaires was >70% for both arms. Global health status improved in 45% of patients in the CAPOX arm and in 21% of patients in the CAPIRI. Some specific variations were observed. In the CAPOX arm, three dimensions-emotional, social, and role-improved with treatment from baseline and nausea and vomiting and fatigue decreased evenly. In the CAPIRI arm, several items such as appetite, insomnia, nausea, and vomiting tended to decrease with treatment, whereas diarrhea and fatigue tended to increase. Neither response to treatment nor occurrence of side effects substantially influenced the changes in patients' QoL.
discussion
Selected elderly patients with metastatic CRC have been treated with combination chemotherapy in clinical trials, but patient numbers are low and subset analyses of these patients in individual trials are underpowered. To address this issue, some pooled analyses and several phase II studies seem to confirm the efficacy and safety of oxaliplatin-and irinotecan-based chemotherapy in elderly patients [3, 4, 9, [11] [12] [13] [17] [18] [19] [20] [21] [22] [23] [24] . Given that the aggregate number of older patients in these often conflicting reports is small, these data should be extrapolated to the majority of older patients with caution, and particularly for patients aged >75 years. This is the first prospective trial evaluating the efficacy and tolerability of CAPOX and CAPIRI in elderly subjects through a head-to-head comparison. Our results show that both chemotherapy schedules in this population are feasible and safe, although CAPIRI was less well tolerated than CAPOX. The efficacy results, with an ORR of 38% for CAPOX and 36% for CAPIRI, a median duration of response of 7 and 6.5 months, and a median TTP of 8 and 7 months, respectively, are similar to those obtained by other authors in series employing capecitabine or another fluoropyrimidine in combination with irinotecan or oxaliplatin in the treatment of elderly patients with advanced CRC [9, [11] [12] [13] [17] [18] [19] [20] [21] [22] [23] [24] . However, the median OS in the CAPOX group appeared close to that of 20 months reported by Tournigand et al. with sequential combination chemotherapy in a nonelderly population [25] . It has been noted that the survival of patients with advanced CRC increases when they receive all three active cytotoxic agents (5-FU/LV, oxaliplatin, and irinotecan) during their disease course [25, 26] . Although the choice to treat elderly patients with a single-agent chemotherapy can sometimes be an acceptable option and the CAIRO and FOCUS results studies [27, 28] encourage this concept, the patients who receive first-line chemotherapy doublets as in our experience have a greater chance of receiving all drugs in the course of their therapy. Thus, the shorter survival of patients enrolled in the CAPIRI arm might be attributable to the lower proportion of subjects who received second-line chemotherapy in this group. The frequent comorbidities and the specific toxicity profile of each combination might also have contributed to this. Based on our findings, it would therefore appear advisable to increase the proportion of elderly patients receiving second-line treatment wherever possible.
A subgroup analysis showed that RR, TTP, and OS remained similar irrespective of patient age in both study arms. This unexpected benefit in the older age group ( ‡75 years) represents a unique finding in the literature. Our results indicate that these patients should not be excluded from the potential advantages of combination chemotherapy.
Although neither response to treatment nor occurrence of side effects substantially influenced the QoL changes, global health status was improved in a greater number of patients with CAPOX than with CAPIRI (45% and 21%, respectively). This is similar to the 42% improvement in PS reported with oxaliplatin in younger patients in the de Gramont et al. study [29] .
Both combination regimens showed good safety profiles, although diarrhea (32% versus 15%) and neutropenia (23% versus 15%) were more common in the CAPIRI arm versus the CAPOX arm. However, these toxicity profiles compare favorably with those reported in other studies in elderly patients; of note, severe diarrhea was observed in 17-40% with irinotecan-based chemotherapy [9, [17] [18] [19] 24] and 0-17% with oxaliplatin-based chemotherapy [11] [12] [13] [20] [21] [22] [23] [24] , and grade 3-4 neutropenia was reported in 20%-40% with irinotecan-based chemotherapy [9, [17] [18] [19] 24] and <15% with oxaliplatin-based chemotherapy [11] [12] [13] [20] [21] [22] [23] [24] in other studies of elderly patients. The low rate of severe oxaliplatin-associated neurotoxicity seems noteworthy and is likely to be related to the median of six cycles administered, resulting in a lower cumulative dose of the platinum analog.
Defining suitable doses for the CAPIRI regimen has been challenging because capecitabine and irinotecan have overlapping toxic effects. We selected doses of 1000 mg/m 2 twice daily on days 1-14 for capecitabine plus irinotecan 80 mg/m 2 on days 1 and 8, keeping in mind the Grothey et al. study [14] . However, of interest are the findings from a more recent Arbeitsgemeinschaft Internistische Onkologie study [30] , which tested a capecitabine-irinotecan regimen at 20% lower doses than had been previously tested (i.e. capecitabine 800 mg/m 2 twice daily on days 1-14 and irinotecan 200 mg/m 2 on day 1) in combination with bevacizumab. This schedule had a favorable tolerability profile without any loss of efficacy and might be of interest for elderly patients. 
